Roche Takes Out The Alzheimer’s Trash

Deal Snapshot: Roche is finally returning the rights to two failed Alzheimer’s candidates. But why now?  

Roche

Who: Roche Holding AG/AC Immune SA

What: Roche has returned all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab to their...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business